XORTX Therapeutics Inc.
XRTX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for XRTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · XRTX
XORTX Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapeutics for kidney diseases, including gout and autosomal dominant polycystic kidney disease (ADPKD), with no approved products or revenue to date.
Key risk: No revenue or profitability
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2021.
XORTX Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapeutics for kidney diseases, including gout and autosomal dominant polycystic kidney disease (ADPKD), with no approved products or revenue to date.
- XORTX has incurred significant losses since inception, with net losses of $2.2M, $3.3M, and $2.7M for the years ended 2023, 2024, and 2025 respectively, and an accumulated deficit of approximately $23.8M as of December 31, 2025 [sec · filed 2026-03-20].
- The company has not generated any revenue to date and expects to continue incurring losses for the foreseeable future [sec · filed 2026-03-20].
- As of December 31, 2021, the company reported cash and equivalents of $18.9M, net income of -$1.7M, and shareholders' equity of $0.3M [sec].
- XORTX is advancing two key programs: XRx-026 (XORLO™) for gout, for which a Type C meeting request was submitted to the FDA in February 2025, and XRx-008 for ADPKD, which is in preparation for registration clinical trials [sec · filed 2026-03-20].
- The company has a limited operating history and has not yet demonstrated the ability to complete any clinical trials, obtain marketing approvals, or commercialize a product [sec · filed 2026-03-20].
What works
- XORTX has identified a clear unmet need in kidney disease treatment, noting that current therapies often only delay disease progression and that there is a need for new therapies with improved efficacy and reduced toxicity [sec · filed 2026-03-20].
- The company has advanced its gout program (XRx-026) to the stage of engaging with the FDA via a Type C meeting request, indicating progress toward a New Drug Application [sec · filed 2026-03-20].
- XORTX believes its proprietary small molecule discovery and formulation capabilities uniquely position it to develop next-generation kidney therapeutics [sec · filed 2026-03-20].
What to weigh
- XORTX has no approved products, no revenue, and an accumulated deficit of approximately $23.8M as of December 31, 2025, with continued losses expected [sec · filed 2026-03-20].
- The company faces significant clinical development risk, as it has not yet demonstrated the ability to successfully complete any clinical trials or obtain regulatory approvals [sec · filed 2026-03-20].
- XORTX will require additional financing to continue operations, and raising capital may cause dilution to shareholders [sec · filed 2026-03-20].
- The company has a limited number of product candidates, with one still in preclinical development, and any setbacks in clinical trials could materially adversely affect the business [sec · filed 2026-03-20].
From the filings
Quoted directly from source documents.
XORTX has not generated any revenue and may never be profitable.
“We have not generated any revenue to date and may never be profitable.”
SEC filings · March 20, 2026
The company has incurred significant net losses and an accumulated deficit.
“Our net losses for the years ended December 31, 2023, 2024 and 2025 were US$2,158,065, US$3,313,346 and US$2,656,304 respectively. As of December 31, 2025, our accumulated deficit was approximately US$23,824,557.”
SEC filings · March 20, 2026
XORTX submitted a Type C meeting request to the FDA for its gout program.
“On February 24, 2025, the Company submitted a Type C meeting request to the FDA regarding its XRx-026 program for the treatment of gout.”
SEC filings · March 20, 2026
Risks & what to watch (4)›
Key risks
- No revenue or profitability — XORTX has no approved products and has never generated revenue; it expects to continue incurring losses [sec · filed 2026-03-20].
- Clinical development risk — The company has not completed any clinical trials and faces significant risk of setbacks in advanced trials [sec · filed 2026-03-20].
- Need for additional capital — XORTX will require additional financing to continue operations, which may cause shareholder dilution [sec · filed 2026-03-20].
- Limited product pipeline — The company has a limited number of product candidates, with one still in preclinical development [sec · filed 2026-03-20].
What to watch
- Outcome of the FDA Type C meeting for the XRx-026 gout program, which will inform the path to a New Drug Application [sec · filed 2026-03-20].
- Progress of XRx-008 for ADPKD, including preparation for registration clinical trials [sec · filed 2026-03-20].
- Ability to secure additional financing to fund ongoing operations and clinical development [sec · filed 2026-03-20].
- Any updates on the company's ability to achieve regulatory approval and commercialization milestones [sec · filed 2026-03-20].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run XORTX Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available XORTX Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
9.5 months
D/E 0.32
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Short Interest
as of May 22, 2026- % of float
- 5.3%
- Days to cover
- 0.0
- Shares short
- 79,644
- Daily short volume (Aug 28, 2026)
- 12.8%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
XRTX short interestFrequently asked questions
What is the AI investment thesis for XORTX Therapeutics Inc.?
XORTX Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapeutics for kidney diseases, including gout and autosomal dominant polycystic kidney disease (ADPKD), with no approved products or revenue to date.
Who is the CEO of XORTX Therapeutics Inc.?
Dr. Allen Warren Davidoff Ph.D. is the chief executive officer of XORTX Therapeutics Inc. (XRTX).
Where is XORTX Therapeutics Inc. headquartered?
XORTX Therapeutics Inc. (XRTX) is headquartered in Calgary, AB, Canada.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.